🇪🇺EU · EMAApplication withdrawnATC: L01CD02

Docetaxel SUN

Prostatic Neoplasms;Carcinoma, Non-Small-Cell Lung;Gastrointestinal Neoplasms;Breast Neoplasms;Head and Neck Neoplasms

Marketing Authorisation Holder: Sun Pharmaceutical Industries Europe B.V.

INN: docetaxel

Indication

Treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Docetaxel SUN — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Docetaxel SUN Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.